TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9174388

Group type: EXPERIMENTAL
Intervention: PGE1 treatment (60 micrograms PGE1 in 250 ml of physiological saline, twice daily for 3 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PGE1 treatment
Number of subjects: 83
Study: 1359619

Group type: EXPERIMENTAL
Intervention: AZT (300 mg/day) + ACV (600 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: AZT (300 mg/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZT + ACV (in patients with >200 CD4 cells/microL at diagnosis)
Number of subjects: 26

Group type: COMPARATOR
Intervention: AZT (in patients with <200 CD4 cells/microL at diagnosis)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZT + ACV
Number of subjects: 26

Group type: COMPARATOR
Intervention: AZT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 26
Study: 3099268

Group type: EXPERIMENTAL
Intervention: Cefaclor (20 mg/kg/day for 10 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Penicillin V potassium (20 mg/kg/day for 10 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Oral cephalosporins (combined data from five studies)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Penicillin (combined data from five studies)
Number of subjects: 104
Study: 30624003

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 75
Study: 29129253

Group type: EXPERIMENTAL
Intervention: Orsiro bioresorbable polymer sirolimus‐eluting stent (BP SES)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Xience durable polymer everolimus‐eluting stent (DP EES)
Number of subjects: 1334
Study: 26831677

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 62
Study: 25095846

Group type: EXPERIMENTAL
Intervention: Kefir drink (100 ml per day for 2 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sodium fluoride rinse (0.05% for 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Kefir drink (after washout period)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sodium fluoride rinse (after washout period)
Number of subjects: 22
Study: 22721966

Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Duodenal nutrition perfusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exendin(9-39) infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose-related stimulation of ISR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GLP-1 and GIP secretions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Incretin effect
Number of subjects: 24
Study: 19670096

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with regional hyperthermia (RHT)
Number of subjects: 46
Study: 17924282

Group type: EXPERIMENTAL
Intervention: TVE‐DSE in DM + MA
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: TVE‐DSE in DM - MA
Number of subjects: 71

Group type: COMPARATOR
Intervention: TVE‐DSE in Controls
Number of subjects: 71
Study: 15141795

Group type: EXPERIMENTAL
Intervention: Desflurane at 1 and 2 MAC in nitrous oxide/oxygen (55%/45%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 and 2 MAC in nitrous oxide/oxygen (55%/45%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both desflurane and sevoflurane
Number of subjects: 0
Study: 11588634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 9861862

Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen (HbsAg) and antibodies to hepatitis B virus (anti‐HBV)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Anti‐HCV
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Anti‐HTLV‐1
Number of subjects: 63

Group type: COMPARATOR
Intervention: Anti‐HIV and anti‐HDV
Number of subjects: 63
Study: 10158378

Group type: EXPERIMENTAL
Intervention: Magnum 0.021 inch wire
Number of subjects: 723
Study: 2778791

Group type: EXPERIMENTAL
Intervention: lisinopril (20-40 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: captopril (25-50 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 12

Group type: COMPARATOR
Intervention: captopril
Number of subjects: 12
Study: 321288

Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Halofenate with phenformin plus chlorpropamide or tolbutamide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 47
Study: 31674091

Group type: EXPERIMENTAL
Intervention: Planned Vaginal Delivery (VD)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Planned Cesarean Delivery (CD)
Number of subjects: 1391
Study: 31820116

Group type: EXPERIMENTAL
Intervention: Automated reminder calls in addition to usual care
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care telephone reminders
Number of subjects: 301
Study: 28832557

Group type: EXPERIMENTAL
Intervention: Conventional care plus self‐efficacy interventions (health education, behavior therapy, psychological intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional care plus self‐efficacy interventions
Number of subjects: 120
Study: 23186131

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21108868

Group type: EXPERIMENTAL
Intervention: Combat simulation group (assessed immediately after battlefield simulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (assessed shortly before battlefield simulation)
Number of subjects: 0
Study: 19749494

Group type: EXPERIMENTAL
Intervention: efonidipine hydrochloride ethanolate 40 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: amlodipine besilate 5 mg/day
Number of subjects: 40
Study: 17093150

Group type: EXPERIMENTAL
Intervention: 10 mg Cuban sugar cane policosanol (SCP) per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (incorporated in margarine)
Number of subjects: 21
Study: 15055092

Group type: EXPERIMENTAL
Intervention: High-strength magnetic knee sleeve treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo-magnetic knee sleeve treatment
Number of subjects: 29
Study: 11717621

Group type: EXPERIMENTAL
Intervention: Heart failure patients (mild-to-moderate symptoms, NYHA classes I and II)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart failure patients (severe symptoms, NYHA classes III and IV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart failure patients (all classes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart failure patients (adjusted for confounders)
Number of subjects: 24
Study: 9156046

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (2 cigarettes) in diabetic smokers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (2 cigarettes) in normal smokers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin tolerance test (0.15 U/kg body weight) in diabetic smokers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin tolerance test (0.15 U/kg body weight) in normal non-smokers
Number of subjects: 20
Study: 8127283

Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg for gastroscopy, 4 mg for colonoscopy)
Number of subjects: 1025
Study: 6388776

Group type: EXPERIMENTAL
Intervention: Birth room setting
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional setting
Number of subjects: 114
Study: 30421119

Group type: EXPERIMENTAL
Intervention: Laparoscopic Liver Resection Difficulty Score (LDS)
Number of subjects: 444
Study: 30369300

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 8
Study: 26719225

Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 16087

Group type: EXPERIMENTAL
Intervention: Reduced CT Colonography (r‐CTC)
Number of subjects: 16087

Group type: EXPERIMENTAL
Intervention: Full CT Colonography (f‐CTC)
Number of subjects: 16087

Group type: EXPERIMENTAL
Intervention: Optical Colonoscopy (OC)
Number of subjects: 16087
Study: 25142085

Group type: EXPERIMENTAL
Intervention: Withholding hydration
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sodium bicarbonate hydration (1-h 250 mL 1.4%)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sodium bicarbonate hydration
Number of subjects: 138
Study: 22132722

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg, 0.05 mL of solution prepared from avastin, 100 mg/4 mL vial) at the end of surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (phacoemulsification with intraocular lens implantation alone)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 20664198

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2091
Study: 17684208

Group type: EXPERIMENTAL
Intervention: Fat-free milk (n = 18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fat-free soy protein (n = 19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Maltodextrin (control group; n = 19)
Number of subjects: 56
Study: 16522417

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with low-dose oxytocin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with high-dose oxytocin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Opioid analgesia
Number of subjects: 19
Study: 15278044

Group type: EXPERIMENTAL
Intervention: Computer-based simulator training (10 hours)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-pretrained group
Number of subjects: 22
Study: 10981820

Group type: EXPERIMENTAL
Intervention: Pulsating magnetic field (induction: 25-80 microT; frequency: 200 Hz) applied for 3 weeks (5 days/week, twice a day for 8 minutes each)
Number of subjects: 7
Study: 8814695

Group type: EXPERIMENTAL
Intervention: Involved radiotherapy alone or radiotherapy plus 6 months of chlorambucil in limited disease (Ann Arbor stage I and II)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Chemotherapy in disseminated disease (Ann Arbor stage III)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Ann Arbor stage I disease
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Ann Arbor stage II disease
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Ann Arbor stage III disease
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Ann Arbor stage IV disease
Number of subjects: 398
Study: 1706244

Group type: COMPARATOR
Intervention: beta-hCG vaccine formulations
Number of subjects: 18
Study: 6594926

Group type: EXPERIMENTAL
Intervention: VP-16-213
Number of subjects: 38
Study: 30998721

Group type: EXPERIMENTAL
Intervention: Vernal keratoconjunctivitis prevalence
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Close animal contact
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Dust exposure
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Personal systemic allergy history
Number of subjects: 574
Study: 28619303

Group type: EXPERIMENTAL
Intervention: Light pressure stroking massage with sesame oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Liquid paraffin (placebo)
Number of subjects: 40
Study: 25548091

Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding course for 10 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (age matched to riders)
Number of subjects: 15
Study: 23245772

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study: 20935058

Group type: EXPERIMENTAL
Intervention: 1 day of 0.25 mg palonosetron
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 2 days of 0.25 mg palonosetron
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 3 days of 0.25 mg palonosetron
Number of subjects: 73
Study: 19840579

Group type: EXPERIMENTAL
Intervention: 75 mg of clopidogrel for 30 days (group II)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 150 mg of clopidogrel (group III)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 75 mg of clopidogrel (group I)
Number of subjects: 59
Study: 16938749

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (intended INR 1.3-1.9)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no warfarin)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 15522049

Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD) patients
Number of subjects: 40
Study: 10902794

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 11990165

Group type: EXPERIMENTAL
Intervention: Albuterol administered via Rotahaler at various altitudes
Number of subjects: 19
Study: 7870942

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3774871

Group type: EXPERIMENTAL
Intervention: Femoxetine (600 mg daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amitriptyline (150 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 81
Study: 31881995

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) specific for LLD, delivered in 15 sessions over 8 weeks (twice per week) with a 6-month follow-up period.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Supportive unspecific intervention (SUI) of the same quantity as CBT.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) specific for LLD.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Supportive unspecific intervention (SUI).
Number of subjects: 248
Study: 30387904

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pimavanserin with cognitive-enhancing medication
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Pimavanserin without cognitive-enhancing medication
Number of subjects: 335
Study: 27447961

Group type: EXPERIMENTAL
Intervention: Multimodal outreach (letter/email/telephone)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Telephone outreach
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Multimodal outreach
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Letter outreach
Number of subjects: 1100
Study: 24401360

Group type: EXPERIMENTAL
Intervention: Vitreous application 2 + etching (G5)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vitreous application 1 + etching with hydrofluoric acid (G3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (G1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Air‐borne particle abrasion with silica‐coated aluminum oxide particles (G2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vitreous application 1 + tribosilicatization (G4)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Vitreous application 2 + tribosilicatization (G6)
Number of subjects: 84
Study: 22684617

Group type: EXPERIMENTAL
Intervention: Polynephron dialyzer
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-flux polysulphone dialyzer
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both dialyzer groups
Number of subjects: 20
Study: 20153490

Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with NGR (n = 385)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with IGR (n = 189)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: NIMGU in individuals with DM (n = 42)
Number of subjects: 616

Group type: COMPARATOR
Intervention: NIMGU across groups (NGR, IGR, DM)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: NIMGU and percentage body fat
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: NIMGU and 24-hour energy expenditure
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: NIMGU and sleep energy expenditure
Number of subjects: 616
Study: 18982860

Group type: COMPARATOR
Intervention: Chinese subjects
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Other countries subjects
Number of subjects: 1236
Study: 15644072

Group type: EXPERIMENTAL
Intervention: Danshen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Buflomedil
Number of subjects: 33

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 33
Study: 11601563

Group type: EXPERIMENTAL
Intervention: UFA margarine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 16

Group type: COMPARATOR
Intervention: Jelly
Number of subjects: 16

Group type: COMPARATOR
Intervention: UFA margarine + jelly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cracker alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: No oral stimulation
Number of subjects: 16
Study: 9862944

Group type: EXPERIMENTAL
Intervention: Atovaquone (1500 mg daily)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Dapsone (100 mg daily)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Dapsone
Number of subjects: 1057
Study: 8077767

Group type: EXPERIMENTAL
Intervention: Chinese hamster glycosylated recombinant interferon‐beta (rHuIFN‐beta)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Natural IFN‐beta (Frone)
Number of subjects: 12
Study: 2792395

Group type: EXPERIMENTAL
Intervention: Fecatwin/Feca EIA (combined guaiac and immunological test)
Number of subjects: 535
Study: 1098594

Group type: EXPERIMENTAL
Intervention: Quinestrol 2 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Quinestrol 4 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 31610998

Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and exercise intervention (12-week multi-modal exercise program)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and exercise intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control/delayed condition
Number of subjects: 68
Study: 28624483

Group type: EXPERIMENTAL
Intervention: HFpEF (LVEF ≥50%)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: HFmrEF (LVEF 40% to 49%)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: HFrEF (LVEF <40%)
Number of subjects: 843
Study: 25989827

Group type: EXPERIMENTAL
Intervention: Reduced glutathione 1800 mg (n=416)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo (n=411)
Number of subjects: 825
Study: 23799707

Group type: EXPERIMENTAL
Intervention: Hypertension control program
Number of subjects: 4902
Study: 21723606

Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Linagliptin 0.5 mg, 2.5 mg, 10 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20070724

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral dydrogesterone
Number of subjects: 69
Study: 16490616

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d plus ezetimibe 10 mg/d
Number of subjects: 203

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/d
Number of subjects: 203
Study: 15072629

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open Prostatectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both HoLEP and Open Prostatectomy
Number of subjects: 120
Study: 10885234

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 intravenous bolus injection followed by 6 mg.kg‐1.h‐1 infusion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ketamine (1 mg.kg‐1 intravenous bolus injection followed by 1 mg.kg‐1.h‐1 infusion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fentanyl (5 micrograms.kg‐1 injection)
Number of subjects: 28
Study: 8836022

Group type: EXPERIMENTAL
Intervention: Individual counseling of patients with STD, combined with contact slip(s)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (no individual counseling)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Individual counseling of women with STD
Number of subjects: 396
Study: 1345803

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: COMPARATOR
Intervention: GM-CSF and Placebo
Number of subjects: 69
Study: 6441958

Group type: EXPERIMENTAL
Intervention: Vasopressin treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30985218

Group type: EXPERIMENTAL
Intervention: Isotretinoin (n = 38)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Systemic antibiotic (n = 17)
Number of subjects: 55
Study: 30120403

Group type: EXPERIMENTAL
Intervention: Experimental Formula (EF) supplemented with bovine milk fat globule membranes
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard Formula
Number of subjects: 160
Study: 25794220

Group type: EXPERIMENTAL
Intervention: Isometric strength training of the neck flexors
Number of subjects: 145